United Therapeutics Corporation vs Sarepta Therapeutics, Inc.: SG&A Expense Trends

Biotech Giants' SG&A Expenses: A Decade of Strategic Growth

__timestampSarepta Therapeutics, Inc.United Therapeutics Corporation
Wednesday, January 1, 201449315000381287000
Thursday, January 1, 201575043000452612000
Friday, January 1, 201683749000316800000
Sunday, January 1, 2017122682000330100000
Monday, January 1, 2018207761000265800000
Tuesday, January 1, 2019284812000336200000
Wednesday, January 1, 2020317875000423900000
Friday, January 1, 2021282660000467000000
Saturday, January 1, 2022451421000487000000
Sunday, January 1, 2023481871000477100000
Loading chart...

Igniting the spark of knowledge

SG&A Expense Trends: United Therapeutics vs. Sarepta Therapeutics

In the competitive landscape of biotechnology, understanding financial trends is crucial. Over the past decade, from 2014 to 2023, United Therapeutics Corporation and Sarepta Therapeutics, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. United Therapeutics consistently maintained higher SG&A expenses, peaking in 2022 with nearly 487 million USD, reflecting a strategic focus on robust administrative and sales operations. In contrast, Sarepta Therapeutics exhibited a more dynamic growth, with SG&A expenses surging by over 870% from 2014 to 2023, reaching approximately 482 million USD. This rapid increase underscores Sarepta's aggressive expansion and investment in administrative capabilities. The data highlights the contrasting strategies of these biotech giants, offering insights into their operational priorities and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025